Review and feature article
The epidemiology and genetics of asthma risk associated with air pollution

https://doi.org/10.1016/j.jaci.2004.12.003Get rights and content

The occurrence of asthma and allergic diseases has continued to increase in the United States and worldwide, despite general improvements in air quality over the past 40 years. This observation has led many to question whether air quality is truly a significant risk factor in the development and exacerbation of asthma and whether further improvement in air quality is likely to result in improved health outcomes. However, epidemiologic studies have shown that levels of pollutants of less than the current ambient air quality standards still result in exacerbations of asthma and are associated with other morbidities as well. Specific locations, such as living near a roadway, might pose a special exposure risk. Genetic factors almost certainly play a role in determining susceptibility to pollutants, such as including those involved with antioxidant defenses. The best studied of these in the context of air pollution risks are glutathione-S-transferase polymorphisms. Irrespective of whether pollutants contribute to the development of asthma or the well-documented increases in asthma results in more people having pollutant-induced disease, poor air quality in many places remains a significant problem for patients with asthma and allergic disease. A number of public health, pharmaceutical, and nutriceutical interventions might mitigate the effects of pollutant exposure and deserve further study.

Section snippets

Epidemiology of air pollutant exposure and asthma

Epidemiologic studies of the effect of air pollution have examined both the exacerbation of lung disease associated with acute exposure to pollutants and the development of lung disease or impairment associated with chronic pollutant exposure. Air pollutants implicated in these effects include those regulated by the US Environmental Protection Agency under the Clean Air Act, including nitrogen dioxide (NO2), ozone, and particulate matter (PM; Table I),1 as well as other agents, including

Genetics of air pollutant response

The immediate effect of air pollutants on airway function in both healthy and allergic persons has been extensively reviewed, and a full review can be found elsewhere.1, 2 However, in considering the genetics of response to pollutants, a brief review of the phenotypes of such responses is warranted. Ozone, NO2, and PM (or various components of PM, including diesel exhaust particles and endotoxin) have all been shown to induce acute inflammatory responses in the airway and, in allergic persons,

Interventions (Table III)

Public health approaches to decrease air pollutants have been shown to have a measurable effect on health outcomes. One example of this occurred in concert with the 1996 Olympic Games held in Atlanta. Coincident with attempts by the local government to decrease ozone generation caused by vehicle exhaust, there was not only a decrease in summer ozone levels but also a significant decrease in asthma morbidity noted during this time.44 Likewise, in Dublin, Ireland, a ban on bituminous coal sales

Future directions

Clearly much remains to be learned by using systems biologic, genomic, and epidemiologic approaches in examining in vivo, cellular, and population responses to pollutant stress. Antioxidants and regulators of inflammation are logical targets for investigation. Traditional therapy that decreases chronic allergic inflammation, such as inhaled corticosteroids, also protects allergic asthmatic subjects (but not healthy individuals) against the effect of challenge with air pollutants. Other

References (64)

  • G.E. Hatch

    Asthma, inhaled oxidants, and dietary antioxidants

    Am J Clin Nutr

    (1995)
  • F.J. Kelly et al.

    Altered lung antioxidant status in patients with mild asthma

    Lancet

    (1999)
  • D. Diaz-Sanchez et al.

    Effect of topical fluticasone propionate on the mucosal allergic response induced by ragweed allergen and diesel exhaust particle challenge

    Clin Immunol

    (1999)
  • J.F. Trapp et al.

    The effect of of glucocorticoids on grain dust-induced airway disease

    Chest

    (1998)
  • N.E. Alexis et al.

    Blunting airway eosinophilic inflammation results in a decreased airway neutrophil response to inhaled LPS in patients with atopic asthma: a role for CD14

    J Allergy Clin Immunol

    (2001)
  • D.B. Peden

    Air pollution: indoor and outdoor

  • R. McConnell et al.

    Prospective study of air pollution and bronchitic symptoms in children with asthma

    Am J Respir Crit Care Med

    (2003)
  • R. McConnell et al.

    Air pollution and bronchitic symptoms in Southern California children with asthma

    Environ Health Perspect

    (1999)
  • Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society

    Health effects of outdoor air pollution

    Am J Respir Crit Care Med

    (1996)
  • L. Dijkstra et al.

    Respiratory health effects of the indoor environment in a population of Dutch children

    Am Rev Respir Dis

    (1990)
  • B. Brunekreef et al.

    Indoor nitrogen dioxide exposure and children's pulmonary function

    J Air Waste Manage Assoc

    (1990)
  • L.M. Neas et al.

    Association of indoor nitrogen dioxide with respiratory symptoms and pulmonary function in children

    Am J Epidemiol

    (1991)
  • R.T. van Strien et al.

    Exposure to NO2 and nitrous acid and respiratory symptoms in the first year of life

    Epidemiology

    (2004)
  • R. McConnell et al.

    Prospective study of air pollution and bronchitic symptoms in children with asthma

    Am J Respir Crit Care Med

    (2003)
  • I. Romieu et al.

    Effects of urban air pollutants on emergency visits for childhood asthma in Mexico City

    Am J Epidemiol

    (1995)
  • I. Romieu et al.

    Effects of air pollution on the respiratory health of asthmatic children living in Mexico City

    Am J Respir Crit Care Med

    (1996)
  • I. Romieu et al.

    Effects of intermittent ozone exposure on peak expiratory flow and respiratory symptoms among asthmatic children in Mexico City

    Arch Environ Health

    (1997)
  • J.F. Gent et al.

    Association of low-level ozone and fine particles with respiratory symptoms in children with asthma

    JAMA

    (2003)
  • R.J. Delfino et al.

    Daily asthma severity in relation to personal ozone exposure and outdoor fungal spores

    Am J Respir Crit Care Med

    (1996)
  • C.A. Pope

    Epidemiology of fine particulate air pollution and human health: biologic mechanisms and who's at risk?

    Environ Health Perspect

    (2000)
  • C.A. Pope

    Respiratory hospital admissions associated with PM10 pollution in Utah, Salt Lake, and Cache Valleys

    Arch Environ Health

    (1991)
  • C.A. Pope

    Respiratory disease associated with community air pollution and a steel mill, Utah Valley

    Am J Public Health

    (1989)
  • Cited by (124)

    • Fine particles exposure and cardiopulmonary morbidity in Jeddah: A time-series analysis

      2019, Science of the Total Environment
      Citation Excerpt :

      The WHO's international agency for research on cancer (IARC) classifies air pollution as a ‘Group 1’ carcinogen (IARC, 2013). Several epidemiological studies have previously shown that exposure to PM2.5 increases the risk for morbidity and mortality due to cardiopulmonary diseases (Pope et al., 2015; Brook et al., 2010; Pope and Dockery, 2006; Pope et al., 2004) as well as exacerbate the pre-existing medical conditions such as asthma, coronary obstructive pulmonary disease (COPD) (Peden, 2005; Sunyer et al., 2000) and other respiratory ailments especially among the elderly and children (Cançado et al., 2006). Also, from experimental studies exposure to PM2.5 has been shown to induce respiratory (Harkema et al., 2004; Morishita et al., 2004) and cardiovascular (Bagate et al., 2006; Watkinson et al., 2003) health outcomes and animals with pre-existing cardiopulmonary conditions are even more susceptible to adverse effects of exposure to PM2.5 (Wagner et al., 2012; Kang et al., 2002).

    View all citing articles on Scopus

    (Supported by a grant from GlaxoSmithKline, Inc, Research Triangle Park, NC)

    Series editor: Harold S. Nelson, MD

    Disclosure of potential conflict of interest: David Peden has consultant arrangements with GlaxoSmithKline; has received grants–research support from the National Institutes of Health, the US Environmental Protection Agency, and GlaxoSmithKline; and is on the Speakers' Bureau for GlaxoSmithKline, AstraZeneca, and Merck.

    View full text